NASDAQ:APGE Apogee Therapeutics (APGE) Stock Price, News & Analysis $52.95 -0.39 (-0.73%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Apogee Therapeutics alerts: Email Address About Apogee Therapeutics Stock (NASDAQ:APGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Apogee Therapeutics alerts:Sign Up Key Stats Today's Range$52.64▼$55.0050-Day Range$40.36▼$53.3452-Week Range$14.19▼$72.29Volume347,215 shsAverage Volume512,301 shsMarket Capitalization$3.10 billionP/E RatioN/ADividend YieldN/APrice Target$78.50Consensus RatingBuy Company OverviewApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Read More… “Buffett Indicator” Predicts 62% Stock Market Crash (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Apogee Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 47th PercentileApogee Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 620th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingApogee Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageApogee Therapeutics has received no research coverage in the past 90 days.Read more about Apogee Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Apogee Therapeutics are expected to decrease in the coming year, from ($2.57) to ($3.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apogee Therapeutics is -10.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apogee Therapeutics is -10.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApogee Therapeutics has a P/B Ratio of 7.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Apogee Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.82% of the float of Apogee Therapeutics has been sold short.Short Interest Ratio / Days to CoverApogee Therapeutics has a short interest ratio ("days to cover") of 18.6, which indicates bearish sentiment.Change versus previous monthShort interest in Apogee Therapeutics has recently increased by 1.10%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApogee Therapeutics does not currently pay a dividend.Dividend GrowthApogee Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted22.82% of the float of Apogee Therapeutics has been sold short.Short Interest Ratio / Days to CoverApogee Therapeutics has a short interest ratio ("days to cover") of 18.6, which indicates bearish sentiment.Change versus previous monthShort interest in Apogee Therapeutics has recently increased by 1.10%, indicating that investor sentiment is decreasing. News and Social Media2.3 / 5News Sentiment1.16 News SentimentApogee Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Apogee Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for APGE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Apogee Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,218,774.00 in company stock.Percentage Held by Insiders36.10% of the stock of Apogee Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apogee Therapeutics' insider trading history. Receive APGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APGE Stock News HeadlinesInsider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 6,665 Shares of StockSeptember 7, 2024 | insidertrades.comInsider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) CFO Sells 6,000 Shares of StockAugust 24, 2024 | insidertrades.comWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.September 19, 2024 | Weiss Ratings (Ad)Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation SummitSeptember 12, 2024 | globenewswire.comApogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial OfficerSeptember 9, 2024 | globenewswire.comApogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 40,000 SharesSeptember 9, 2024 | americanbankingnews.comInsider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE)September 7, 2024 | finance.yahoo.comInsider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)August 24, 2024 | finance.yahoo.comSee More Headlines APGE Stock Analysis - Frequently Asked Questions How have APGE shares performed this year? Apogee Therapeutics' stock was trading at $27.94 at the beginning of the year. Since then, APGE stock has increased by 89.5% and is now trading at $52.95. View the best growth stocks for 2024 here. How were Apogee Therapeutics' earnings last quarter? Apogee Therapeutics, Inc. (NASDAQ:APGE) posted its quarterly earnings data on Monday, August, 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.60). When did Apogee Therapeutics IPO? Apogee Therapeutics (APGE) raised $282 million in an initial public offering on Friday, July 14th 2023. The company issued 17,650,000 shares at a price of $15.00-$17.00 per share. Who are Apogee Therapeutics' major shareholders? Apogee Therapeutics' top institutional shareholders include Driehaus Capital Management LLC (3.62%), Perceptive Advisors LLC (3.60%), Affinity Asset Advisors LLC (1.43%) and First Turn Management LLC (0.54%). Insiders that own company stock include Nimish P Shah, Michael Thomas Henderson, Carl Dambkowski and Jane Henderson. View institutional ownership trends. How do I buy shares of Apogee Therapeutics? Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/12/2024Today9/19/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APGE CUSIPN/A CIK1974640 Webwww.apogeetherapeutics.com Phone650-394-5230FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price Target$78.50 High Stock Price Target$95.00 Low Stock Price Target$43.00 Potential Upside/Downside+44.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.05% Return on Assets-19.33% Debt Debt-to-Equity RatioN/A Current Ratio27.70 Quick Ratio27.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.50 per share Price / Book7.24Miscellaneous Outstanding Shares58,456,000Free Float37,353,000Market Cap$3.17 billion OptionableOptionable Beta2.75 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:APGE) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredDump Nvidia, Apple, and Tesla Before It’s Too LateThe financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumpi...InvestorPlace | SponsoredThe $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.